The board of directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that Exarane (an enoxaparin sodium injection and one of the Group's leading drugs) produced by Shenzhen Techdow Medicine Co., Ltd., a wholly-owned subsidiary of the Company, has been approved by New Zealand Medicines and Medical Devices Safety Authority for sales in the market. Trade name is Exarane. Dosage form is Prefilled solution for injection.

Strength is 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/mL, 120mg/0.80mL, 150mg/mL. This approval means that the Group's enoxaparin sodium finish dose will be sold in the New Zealand market, further enhancing the Group's market share of enoxaparin sodium finish dose worldwide.